



# ASO Visual Abstract: Impact of Imaging-Guided Localization on Performance of Tailored Axillary Surgery in Patients with Clinically Node-Positive Breast Cancer: Prospective Cohort Study Within TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101)

Walter P. Weber, MD<sup>1,2</sup>, Martin Heidinger, MD<sup>1,2</sup>, Stefanie Hayoz, PhD<sup>3</sup>, Zoltan Matrai, MD, PhD<sup>4</sup>, Christoph Tausch, MD<sup>2,5</sup>, Guido Henke, MD<sup>6,7</sup>, Daniel R. Zwahlen, MD<sup>8</sup>, Günther Gruber, MD<sup>9</sup>, Frank Zimmermann, MD<sup>2,10</sup>, Giacomo Montagna, MD, MPH<sup>11</sup>, Mariacarla Andreozzi, PhD<sup>1,2</sup>, Maite Goldschmidt, MSc<sup>1,2</sup>, Alexandra Schulz, MSc<sup>2,12</sup>, Andreas Mueller, MD<sup>3,13</sup>, Markus Ackerknecht, PhD<sup>2,14</sup>, Ekaterini Christina Tampaki, MD, PhD<sup>15</sup>, Vesna Bjelic-Radisic, MD<sup>16</sup>, Christian Kurzeder, MD<sup>1,2</sup>, Ákos Sávolt, MD, PhD<sup>17</sup>, Viktor Smánykó, MD<sup>18</sup>, Daniela Hagen, MD<sup>13</sup>, Dieter J. Müller, MD<sup>19</sup>, Michael Gnant, MD<sup>20,21</sup>, Sibylle Loibl, MD<sup>22</sup>, Florian Fitzal, MD<sup>21,23</sup>, Pagona Markellou, MD<sup>7</sup>, Inga Bekes, MD<sup>7</sup>, Daniel Egle, MD<sup>21,24</sup>, Jörg Heil, MD<sup>25</sup>, and Michael Knauer, MD, PhD<sup>26</sup>

<sup>1</sup>Breast Center, University Hospital Basel, Basel, Switzerland; <sup>2</sup>University of Basel, Basel, Switzerland; <sup>3</sup>SAKK Competence Center, Bern, Switzerland; <sup>4</sup>Department of Oncoplastic Breast Surgery, Hamad Medical Corporation, Doha, Qatar; <sup>5</sup>Breast Center Zurich, Zurich, Switzerland; <sup>6</sup>Department of Radiation Oncology, St. Gallen Cantonal Hospital, St. Gallen, Switzerland; <sup>7</sup>Breast Center, St. Gallen Cantonal Hospital, St. Gallen, Switzerland; <sup>8</sup>Department of Radiation Oncology, Cantonal Hospital Winterthur, Winterthur, Switzerland; <sup>9</sup>Institute of Radiotherapy, Zurich, Switzerland; <sup>10</sup>Clinic of Radiation Oncology, University Hospital Basel, Basel, Switzerland; <sup>11</sup>Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY; <sup>12</sup>Department of Clinical Research, University Hospital Basel, Basel, Switzerland; <sup>13</sup>Breast Center, Cantonal Hospital Winterthur, Winterthur, Switzerland; <sup>14</sup>Department of Biomedicine, University Hospital Basel, Basel, Switzerland; <sup>15</sup>Department of Plastic, Reconstructive Surgery and Burn Unit, KAT Athens Hospital and Trauma Center, Athens, Greece; <sup>16</sup>Breast Unit, Helios University Clinic, University Witten, Herdecke, Germany; <sup>17</sup>National Institute of Oncology, Budapest, Hungary; <sup>18</sup>National Tumor Biology Laboratory, National Institute of Oncology, Budapest, Hungary; <sup>19</sup>Bethesda Spital AG, Basel, Switzerland; <sup>20</sup>Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; <sup>21</sup>Austrian Breast and Colorectal Cancer Study Group, ABCSG, Vienna, Austria; <sup>22</sup>German Breast Group, GBG Forschungs GmbH, Neu-Isenburg, Germany; <sup>23</sup>Atomos Klinik Waehring, Vienna, Austria; <sup>24</sup>Breast Cancer Center Tirol, Department of Gynecology, Medical University Innsbruck, Innsbruck, Austria; <sup>25</sup>Breast Center Heidelberg, Heidelberg, Germany; <sup>26</sup>Tumor and Breast Center Eastern Switzerland, St. Gallen, Switzerland

Part of this work was orally presented in Boston, on podium, during the annual conference of the Society of Surgical Oncology (SSO 2023)–International Conference on Surgical Cancer Care, on 25 March 2023.

Walter P. Weber and Martin Heidinger have contributed equally to this work.

© Society of Surgical Oncology 2023


Published online: 13 November 2023

W. P. Weber, MD  
e-mail: walter.weber@usb.ch

Tailored axillary surgery (TAS) selectively removes positive nodes in patients with clinically node-positive breast cancer. In this prospective study (<https://doi.org/10.1245/s10434-023-14404-4>), imaging-guided localization of nodes did not change the performance of TAS.

*Trial Registration:* ClinicalTrials.gov Identifier: NCT03513614.

## Impact of Imaging-Guided Localization on Performance of Tailored Axillary Surgery in Patients With Clinically Node-Positive Breast Cancer: Prospective Cohort Study Within TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101)



**FUNDING** This trial was supported by research agreements with the following institutions: Swiss State Secretary for Education, Research and Innovation (SERI), Swiss Cancer Research Foundation (SCR), and Swiss Cancer League (SCL), and was also supported by grants from the following organizations: Fond'Action contre le cancer, Rising Tide Foundation for Clinical Cancer Research (RTFCCR), Cancer League Basel, Claudia von Schilling Foundation for Breast Cancer Research, Kaempf-Bötschi Foundation, Cancer League Zentralschweiz, Cancer League Thurgau, Cancer League Wallis, Cancer League Aargau, Giuliana und Giorgio Stefanini Foundation, Miaso Foundation, Krebsbekämpfung Foundation, Moritz Straus-Foundation, Ehmann Foundation Savognin, Freiwillige Akademische Gesellschaft (FAG), Association Marianne Payot, J&K Wonderland Foundation, SANA Foundation, Fondation pour la Recherche et le Traitement Médical, Parrotia Foundation, SPS Foundation and Domarena Foundation. This work is also financially supported by Agendia Precision Oncology. None of the funders had any role in the design of the study; collection, analysis, and interpretation of the data; or in writing of the manuscript.

**DISCLOSURE** Walter P. Weber received research support from Agendia, paid to the University Hospital Basel, and honoraria for lectures from MSD. Andreas Mueller reports personal fees from Lilly, Novartis, Pfizer, Genomic Health, AstraZeneca, Daiichi Sankyo, Roche, Pierre Fabre, Exact Sciences, Myriad Genetics, Gilead Sciences, MSD, GlaxoSmithKline; grants from Roche and other grants from Vifor Stock. Christian Kurzeder reports honoraria from Tesaro, GSK, AstraZeneca, Novartis, PharmaMar, Genomic Health, Roche, Eli Lilly S.A., Pfizer, and Daichi; consulting or advisory roles for Tesaro, GSK, AstraZeneca, Novartis, PharmaMar, Genomic Health, Roche, Eli Lilly S.A., Merck MSD, and Pfizer; and travel, accommodations and

expenses from GSK, AstraZeneca, and Roche. Michael Gnant reports personal fees/travel support from AstraZeneca, DaiichiSankyo, Eli Lilly, Menarini-Stemline, MSD, Novartis, PierreFabre, and Veracyte. In addition, he reports that an immediate family member is employed by Sandoz. Sibylle Loibl reports grants from AstraZeneca, Abbvie DSI, Molecular Health, BMS/Celgene, Gilead, Novartis, Pfizer, and Roche; honorarium for advisory board membership; presentations from AstraZeneca, Amgen, Gilead, BMS, Novartis, Pfizer, Seagen, Sanofi, Relay, Olema, Incyte, Roche, Merck KG, Lilly and GSK; and non-financial medical writing support from AstraZeneca, Pfizer, Roche, Novartis, DSI, and Cellucity outside the submitted work. In addition, Sibylle Loibl reports a patent for VM Scope, with royalties paid to the institute, and patents pending for EP14153692.0, EP21152186.9 and EP15702464.7. Florian Fitzal reports personal fees from Novartis, AstraZeneca, Roche, and MSD. Daniel Egle reports personal fees from AstraZeneca, Daiichi Sankyo, Gilead, MSD, Novartis, Pfizer, and Sirius, and non-financial support from Roche outside the submitted work. Michael Knauer reports grants from Agendia and grants from Swiss Cancer Research during the conduct of this study, and other grants from the Myriad Advisory Board outside the submitted work. Martin Heindinger, Stefanie Hayoz, Zoltan Matrai, Christoph Tausch, Guido Henke, Daniel R. Zwahlen, Günther Gruber, Frank Zimmermann, Giacomo Montagna, Mariacarla Andreozzi, Maite Goldschmidt, Alexandra Schulz, Markus Ackerknecht, Ekaterini Christina Tampaki, Vesna Bjelic-Radicic, Ákos Sávolt, Viktor Smanyakó, Daniela Hagen, Dieter J. Müller, Pagona Markellou, Inga Bekes, and Jörg Heil report no conflicts of interest.

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.